These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2720174)

  • 1. Morphological and immunological changes of hairy cell leukemia during alpha-2-interferon therapy.
    Fridrik MA; Wahl G; Herbinger W; Schützenberger W; Gastl G; Huber C; Krönke M; Höpfel I
    Blut; 1989 May; 58(5):261-4. PubMed ID: 2720174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment.
    Marolleau JP; Henni T; Gaulard P; Le Couedic JP; Gourdin MF; Divine M; Katz A; Tulliez M; Goossens M; Reyes F
    Blood; 1988 Aug; 72(2):655-60. PubMed ID: 2840988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients.
    Sainati L; Matutes E; Mulligan S; de Oliveira MP; Rani S; Lampert IA; Catovsky D
    Blood; 1990 Jul; 76(1):157-62. PubMed ID: 2364167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.
    Thaler J; Denz H; Dietze O; Gastl G; Ho AD; Gattringer C; Greil R; Lechleitner M; Huber C; Huber H
    Leuk Res; 1989; 13(5):377-83. PubMed ID: 2787447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hairy cell leukemia: a model for studying the B cell family of diseases.
    Al-Katib A; Berman E; Black P; Koziner B
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):48-54. PubMed ID: 3492047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia.
    Babusíková O; Hrivnáková A; Klobusická M; Mesárosová A; Ujházy P
    Neoplasma; 1990; 37(6):693-701. PubMed ID: 2125699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
    Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
    Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alpha.
    Giardina SL; Young HA; Faltynek CR; Jaffe ES; Clark JW; Steis RG; Urba WJ; Mathieson BJ; Gralnick H; Lawrence J
    Blood; 1988 Nov; 72(5):1708-16. PubMed ID: 2846090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular study of hairy cell leukemia variant with biclonal paraproteinemia.
    Copeland AR; Bueso-Ramos C; Liu FJ; Kornblau SM; Huh YO; Albitar M
    Arch Pathol Lab Med; 1997 Feb; 121(2):150-4. PubMed ID: 9126043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between immunological phenotype and hematological response to alpha-IFN treatment in 35 patients with hairy cell leukemia.
    Lauria F; Zinzani PL; Raspadori D; Foà R; Buzzi M; Gugliotta L; Bocchia M; Benfenati D; Tura S
    Eur J Haematol Suppl; 1990; 52():3-6. PubMed ID: 2279543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha 2-interferon.
    Naeim F; Jacobs AD
    Hum Pathol; 1985 Dec; 16(12):1200-5. PubMed ID: 4065882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
    Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
    Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
    Bardawil RG; Ratain MJ; Golomb HM; Bitter MA; Groves C; Vardiman JW
    Leukemia; 1987 Apr; 1(4):340-3. PubMed ID: 3669760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell prolymphocytic leukemia expressing CD13 antigen.
    Matsushita A; Nagai K; Ishikawa T; Tatsumi E; Ohno Y; Takahashi T
    Int J Hematol; 1994 Aug; 60(2):157-61. PubMed ID: 7524729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
    Matutes E; Owusu-Ankomah K; Morilla R; Garcia Marco J; Houlihan A; Que TH; Catovsky D
    Leukemia; 1994 Oct; 8(10):1640-5. PubMed ID: 7523797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effect of interferon-alpha on hairy cell leukemia].
    Abe Y; Sakai K; Igarashi T; Ishibashi T; Shiga T; Uchida T; Kariyone S
    Rinsho Ketsueki; 1989 Apr; 30(4):535-40. PubMed ID: 2769975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of hairy cell leukemia with interferon].
    Brünig K; Fülle HH; Dahmen E; Hellriegel KP
    Onkologie; 1988 Aug; 11(4):159-65. PubMed ID: 3054667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hairy cell leukemia. Immunological study.
    Stela R; Berceanu S; Munteanu N; Ursea C; Motoiu I; Moraru I
    Haematologia (Budap); 1990; 23(4):211-21. PubMed ID: 2101805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype.
    Lauria F; Raspadori D; Foa R; Zinzani PL; Buzzi M; Gugliotta L; Macchi S; Tura S
    Cancer; 1990 May; 65(10):2233-6. PubMed ID: 1693308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.